Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
207 hedge funds and large institutions have $1.85B invested in Day One Biopharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 61 increasing their positions, 47 reducing their positions, and 57 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
144% more capital invested
Capital invested by funds: $758M → $1.85B (+$1.09B)
47% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 57
30% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 47
13% more funds holding
Funds holding: 183 → 207 (+24)
4.81% more ownership
Funds ownership: 79.29% → 84.09% (+4.8%)
20% less call options, than puts
Call options by funds: $37.8M | Put options by funds: $47.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$66M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$58.2M |
| 3 |
KC
Kryger Capital
London,
United Kingdom
|
+$54.9M |
| 4 |
JP Morgan Chase
New York
|
+$43.6M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$34.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$80.2M |
| 2 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$59.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$48.5M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$42M |
| 5 |
BlackRock
New York
|
-$25.3M |
DAWN Hedge Fund Activity: Q1 2026 in Review
207 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2026, worth a combined $1.85B — up 144% from $758M a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new DAWN positions and 57 closed out — a net gain of 27 holders — while 61 added to existing stakes and 47 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $66M. The largest seller was Fidelity Investments, cutting an estimated $80.2M.
- 207 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2026, up from 183 in Q4 2025.
- Funds reported $1.85B of Day One Biopharmaceuticals stock for Q1 2026, up 144% quarter-over-quarter.
- 84 funds opened new Day One Biopharmaceuticals positions in Q1 2026 and 57 closed out, a net change of +27 holders.
- The largest Day One Biopharmaceuticals buyer in Q1 2026 was Glazer Capital LLC, an estimated $66M added.
- The largest Day One Biopharmaceuticals seller in Q1 2026 was Fidelity Investments, an estimated $80.2M sold.
Based on aggregated 13F filings for Q1 2026.